MGFA has partnered with Bionews to feature the “Myasthenia Gravis News” feed on our MGFA website. We are excited to offer the MG Community this insightful and informative news feed that covers many aspects of living with myasthenia – from research and study results to managing MG, helpful tips, and important news from across the MG World.
Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, BioNews seeks the opinion of outside experts for interviews and Q&As.
Myasthenia Gravis News – The Web’s Daily Resource for Myasthenia Gravis News
- Kyverna planning to launch Phase 3 trial of KYV-101 in MG patientsby Marisa Wexler, MS on May 15, 2025 at 2:45 pm
Kyverna Therapeutics is planning to launch a Phase 3 clinical trial testing its experimental cell therapy KYV-101 in people with myasthenia gravis (MG). The announcement follows an end-of-Phase 2 meeting The post Kyverna planning to launch Phase 3 trial of KYV-101 in MG patients appeared first on Myasthenia Gravis News.
- On representation, community content, and chronic illnessby Sarah Bendiff on May 15, 2025 at 2:00 pm
Last year, when I started a new job, I was asked to create funny, educational videos. The first topic I tackled was “Celebrities You Didn’t Know Have an Invisible Disability.” The post On representation, community content, and chronic illness appeared first on Myasthenia Gravis News.
- Cartesian launching 2 clinical trials testing Descartes-08 in MGby Marisa Wexler, MS on May 14, 2025 at 5:30 pm
Cartesian Therapeutics is gearing up for two clinical trials of its cell therapy Descartes-08: the first, a Phase 3 study, will enroll adults with myasthenia gravis (MG), while the second, The post Cartesian launching 2 clinical trials testing Descartes-08 in MG appeared first on Myasthenia Gravis News.
- 2 new home treatment methods for Rystiggo approved in Japanby Marisa Wexler, MS on May 13, 2025 at 2:00 pm
Japan’s drug regulatory agency has authorized two new administration methods for Rystiggo (rozanolixizumab) — an approved treatment for generalized myasthenia gravis (gMG) — that people with the chronic autoimmune condition The post 2 new home treatment methods for Rystiggo approved in Japan appeared first on Myasthenia Gravis News.
- Why do we experience weakness and falls with myasthenia gravis?by Shawna Barnes on May 12, 2025 at 2:00 pm
I’ve seen these questions pop up in myasthenia gravis (MG) forums more times than I can count: “Why do we get weak? Why do we fall?” If you live with The post Why do we experience weakness and falls with myasthenia gravis? appeared first on Myasthenia Gravis News.
** MGFA Disclaimer – Please read
Myasthenia Gravis Foundation of America (MGFA) and Bionews, Inc. (specifically Myasthenia Gravis News) have entered into a limited agreement that allows for the MGFA to post a link to Myasthenia Gravis News on the myasthenia.org website. Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, Bionews seeks the opinion of outside experts for interviews and Q&As.
The publishing team at Myasthenia Gravis News is made up of science writers and editors, most of whom have PhDs in the life sciences; veteran journalists; and columnists who are members of the MG community. Together, they attempt to ensure that all content published on Myasthenia Gravis News is relevant, accurate, informative, relatable, and easy to understand.
Each piece of content is carefully selected and written by Bionews writers with the MG community in mind. Sources for news stories and resource pages include peer-reviewed studies, press releases, announcements, interviews, webinars, and conference sessions, among others. All articles go through a stringent fact-checking and editing procedure as part of Bionews’ process to ensure they are accurate, objective, comprehensive, and well-explained.
Columns are written by MG patients and caregivers who provide an intimate look at what it’s like to live with the disease. While columns are largely opinion and perspective pieces, each one still goes through a comprehensive editing and fact-checking process by Bionews editors to ensure clarity, accuracy, and fairness.
Myasthenia Gravis News’ site is strictly a news and information website about the disease. It DOES NOT provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The information provided is for educational purposes only and does not substitute for professional medical advice.
The content reflects the unique experiences of the authors and is not necessarily the opinion, views, or recommendations of the MGFA. Medical advisors and clinicians associated with or partnering with the MGFA do not peer review articles and information posted on the Myasthenia Gravis News platform or website. MGFA should not be liable for any information, opinions, articles, advice, guidance, or details posted on the Myasthenia Gravis News site. MGFA has posted this platform as a service to the MG community. Please consult with your doctor and healthcare professionals for specific recommendations and advice pertaining to your healthcare/treatment.